...Ahmad Tawalbeh; Abdulrahman Al-Mashdali; Ahmad Al-Sabbagh; Anil Y. Ellahi; Mohamed A. Yassin Introduction: Chronic myeloid leukemia (CML) is a myeloproliferative neoplasm characterized by the Philadelphia chromosome and uncontrolled granulocyte production. While autoimmune hemolytic anemia (AIHA...

...Darshankumar M. Raval; Ricardo J. Pagán; Shayan Butt; Libardo Rueda Prada Introduction: Chronic myeloid leukemia (CML) is a myeloproliferative disease caused by the reciprocal translocation of chromosomes 9 and 22, which leads to a chimeric gene product known as BCR-ABL. Some studies have shown...

...Awni Alshurafa; Afshan Adil; Mohamed A. Yassin Introduction: Chronic myeloid leukemia (CML) is characterized by the presence of the BCR::ABL1 fusion gene, and the advent of tyrosine kinase inhibitors (TKIs) has revolutionized its therapeutic landscape. Asciminib, a STAMP inhibitor, emerges...

...Awni Alshurafa; Yeslem Ekeibed; Susanna Akiki; Muna Alzeyara; Zafar Nawaz; Mohamed A. Yassin Chronic myeloid leukemia (CML) is a myeloproliferative neoplasm in which granulocytic cells are the main proliferative component. At diagnosis, more than 90% of CML cases have the characteristic...

... with coexisting epidermal growth factor receptor ( EGFR )-mutant lung adenocarcinoma and BCR-ABL1 -positive chronic myeloid leukemia (CML). The patient received afatinib for a postoperative intrapulmonary recurrence of lung adenocarcinoma harboring EGFR exon 19 deletion. Tumor reduction was achieved with afatinib...

...Elrazi A. Ali; Mohammad Abu-Tineh; Mohamed Abdelrazek; Mahir Petkar; Mzaki Karzoun; Eihab A. Subahi; Lajos Szabados; Mohamed A. Yassin Chronic myeloid leukemia (CML) is a hematologic malignancy that has significant improvement in its prognosis after the introduction of tyrosine kinase inhibitors...

...Shinya Yamada; Kotaro Arita; Yukio Kondo; Shuichi Mizuta; Hirokazu Okumura Chronic myeloid leukemia (CML) blast phase (monocytic lineage) is extremely rare. A 39-year-old Japanese man was diagnosed with CML blast phase (monocytic lineage). T315I mutation was positive, ponatinib was initially...

...Brittany M. Smith; Diana Brewer; Brian J. Druker; Theodore P. Braun Quantitative PCR-based strategies are typically effective for monitoring BCR-ABL1 transcript levels in chronic myeloid leukemia (CML). Additionally, some patients treated with tyrosine kinase inhibitors can experience long-term...

...Zakaria Maat; Kamran Mushtaq; Mohamed A. Yassin Dasatinib is a BCR-ABL tyrosine kinase inhibitor which was approved in 2006 for the treatment of adults diagnosed with Philadelphia chromosome-positive (Ph+) chronic myeloid leukemia (CML) in chronic phase (CP) and accelerated (myeloid or lymphoid...

...Kimimori Kamijo; Yoshimitsu Shimomura; Daisuke Yamashita; Takayuki Ishikawa Here, we present a rare case of tyrosine kinase inhibitor (TKI)-induced bone marrow aplasia. A 58-year-old man presented with leukocytosis and was diagnosed with chronic myeloid leukemia. He was initially treated...

...Yousef Mohammed Ali Hailan; Deena Mudawi; Mohamed A. Yassin Chronic myeloid leukemia (CML) is a myeloproliferative disorder diagnosed by demonstrating the Philadelphia chromosome (Ph) or the BCR-ABL fusion gene. Tyrosine kinase inhibitors (TKIs) are the standard of therapy. There are increasing...

...Elrazi Awadelkarim Hamid Ali; Susanna Al-Akiki; Mohamed A. Yassin Chronic myeloid leukemia (CML) is a myeloproliferative neoplasm (MPN) that harbors the Philadelphia chromosomal translocation resulting in the uncontrolled production of mature granulocytes. Commonly, patients are diagnosed with CML...

...Tatsuro Jo; Takahiro Sakai; Kaori Matsuzaka; Kazuhiro Noguchi; Shizuka Hayashi; Masatoshi Matsuo; Jun Taguchi We present the case of a patient with multiple tyrosine kinase inhibitor (TKI)-refractory chronic phase chronic myeloid leukemia (CP-CML) with a T315I mutation of abl1 . Dasatinib, a second...

... monitoring in chronic myeloid leukemia (CML) patients, and it plays a pivotal role in clinical decision-making process, even if it presents technical limits. Increasing data suggest that digital PCR (dPCR) is more accurate and reliable than RT-qPCR in CML minimal residual disease monitoring and in patients...

...Ryo Yanagiya; Daisuke Ishikawa; Tomomi Toubai; Tsubasa Ichikawa; Naofumi Kawaguchi; Kunie Sugasawa; Kenichi Ishizawa; Soichi Saito Although tyrosine kinase inhibitors markedly improve the clinical outcome of chronic myeloid leukemia (CML), blast crisis in CML (CML-BC) still has a poor prognosis...

...Bara M. Al-Qudah; Mohamed A. Yassin; Mohammad A.J. Abdulla; Mahmood S. Aldapt; Mohamad M. Abufaied Chronic myeloid leukemia (CML) is a myeloproliferative neoplasm, classically described as a triphasic disease. However, little is known about risk factors for developing CML. Currently, ionizing...

...Husam N. Al-Dubai; Mohammed A. Yassin; Mohammed A. Abdulla; Mahmood S. Aldapt; Rola S. Ghassoub Chronic myeloid leukemia (CML) is a myeloproliferative neoplasm classically described as triphasic disease: chronic, accelerated, and blast crisis. There are many unmet needs and unanswered questions...

...Osamu Imataki; Tomoya Ishida; Hiroyuki Kubo; Makiko Uemura; Yasuhito Nanya; Kimihiro Kawakami; Seishi Ogawa; Norimitsu Kadowaki Hematological malignancies, including chronic myeloid leukemia (CML), exhibit ASXL1 mutations; however, the function and molecular mechanism of these mutations remain...

...Mohammad Abu-Tineh; Nancy Kassem; Mohammad Abdul-Jaber Abdulla; Omar Mohammad Ismail; Khaldun Obeidat; Rola Ghasoub; Mohamed A. Yassin Chronic myelogenous leukemia (CML), also known as chronic myeloid leukemia, is a myeloproliferative neoplasm characterized by increased proliferation...

...Shehab F. Mohamed; Ahmed Qatami; Abdulqadir Nashwan; Mohammad A. Abdulla; Mohamed A. Yassin Chronic myeloid leukemia (CML) is a myeloproliferative neoplasm, classically described as triphasic disease (chronic, accelerated, and blast). Despite the significant efforts made by different groups...